Provided by Tiger Trade Technology Pte. Ltd.

Atara Biotherapeutics

4.88
+0.37008.20%
Post-market: 4.880.00000.00%19:07 EST
Volume:100.03K
Turnover:482.31K
Market Cap:35.19M
PE:2.22
High:4.92
Open:4.58
Low:4.58
Close:4.51
52wk High:19.15
52wk Low:4.20
Shares:7.21M
Float Shares:4.61M
Volume Ratio:0.81
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.19
EPS(LYR):-11.4053
ROE:-2014.86%
ROA:30.86%
PB:-0.96
PE(LYR):-0.43

Loading ...

Company Profile

Company Name:
Atara Biotherapeutics
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
38
Office Location:
1280 Rancho Conejo Blvd,Thousand Oaks,California,United States
Zip Code:
91320
Fax:
- -
Introduction:
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Directors

Name
Position
AnhCo Nguyen
President, Chief Executive Officer and Director
Carol Gallagher
Lead Independent Director
Gregory A. Ciongoli
Director and Chair of the Board
Matthew K. Fust
Director
William Heiden
Director

Shareholders

Name
Position
AnhCo Nguyen
President, Chief Executive Officer and Director